Market Timing with TurnerTrends Provides Great Stock Picks for the Sophisticated Investor   Timing the Market well requires Stock Picks that work
Home Subscribe! StockMasterPro ETFMasterPro CycleProphet Partners Members
Top 100 Stocks | Search Stocks | Sector Analyzer | Industry Analyzer
New Hot Stock Picks | How we Rate Stocks | Tutorial
My Stock Watch Lists: Add+
Ticker: 

TurnerTrends Stock Rating Report for GENT

Data valid for week beginning March 08, 2010

Ticker Company Name
GENT   [News] Gentium SpA (ADR)
Company Profile
"Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a deoxyribonucleic acid (DNA) based drug derived from pig intestines, to treat and prevent a disease called hepatic veno-occlusive disease (VOD), a condition in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments that are given prior to stem cell transplantation. The Company is concluding a Phase III clinical trial of defibrotide to treat severe VOD in the United States, Canada and Israel. The Company is also conducting a Phase II-III clinical trial of defibrotide in Europe to prevent VOD in children. In addition to defibrotide, the Company sells urokinase, calcium heparin, sodium heparin and sulglicotide, which are active pharmaceutical ingredients used to make other drugs."

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Technical Chart (3 year) Sector Chart Industry Chart

GENT Technical Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for GENT. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Gentium SpA (ADR) next week. Sign up today and start making money!

FREE TRIAL!!


Stock Information
Friday's Close $1.34
Volume Avg. 15102 shares
Industry Biotechnology and Drugs
Sector Healthcare
Our Stop Loss Members Only
Expected Move Members Only
Optionable? No

Stock Financials
Profit Margin .00%
Operating Margin -117.07%
Debt-to-Equity .55%
P/E ttm 0.00
EPS ttm $-0.720
Total Revenue $9,740,000
Market Cap $20,040
Annual Dividend $.00
Yield .000%
ROE 0.50%
Revenue Growth Rate Quarterly 35.20%
Earnings Growth Rate Quarterly 82.50%
Earnings Growth Rate Yearly 0.00%
Multi-Year Average Revenue Growth Rate N/A
Multi-Year Average Earnings Growth Rate N/A
Institutional Ownership Members Only
Value Rating Members Only
TurnerTrends Score  (Range: -100 to 210) Members Only


Home | Stock Ratings | Top 100 Stocks | New Hot Stock Picks | Sector Analyzer | Industry Analyzer | Member's Area | Articles | FAQ | Contact Us | Terms of Use | Advertise
(C) Copyright TurnerTrends, Inc.  All Rights Reserved.

*Past performance does not guarantee future results. TurnerTrends makes no representations or warrants that just because a stock would have made a profit in the past, using TurnerTrends buy recommendations or sell recommendations, it will make any profits in the future. It is possible that these same stocks will lose money in the future using the TurnerTrends stock recommendations.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither TurnerTrends nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the TurnerTrends site, a user agrees not to redistribute the information found therein.